The purpose of the programme is to promote research that contributes to the overarching goal for Sweden’s strategy for the work against antimicrobial resistance: to preserve the option of effective treatment of bacterial infections in humans and animals.
Antimicrobial resistance is a momentous global issue, focused on the use of antibiotics. Humans and animals move across national borders on a daily basis, as do foods and other products. Because of this, they can spread resistant bacteria. More and more bacteria are developing resistance to existing antibiotics, at the same time as the development of new antibiotics has slowed down.
The research programme has a broad, multi-disciplinary and multi-sectoral perspective. All research relating to antimicrobial resistance – both basic research and more applied research – can receive funding. Examples are research into new antibiotics, diagnostic methods or how the spread of infection and healthcare-related infections can be reduced.
20 million SEK to allocate in 2018
For 2018, we have 20 million SEK to allocate to research into antimicrobial resistance and infectious diseases. We will be allocating 25 million SEK in 2019, and the same amount in 2020. Ongoing initiatives made in the area by the Swedish Research Council and other funding bodies may gradually be incorporated in the programme, or become collaborative projects.
Strategic research agenda shall create synergies
We have formed a programme committee for the national research programme consisting of representatives from the research councils Formas, Forte and Vinnova, and also the Swedish Agency for Marine and Water Management, the Swedish International Development Cooperation Agency (Sida), the Public Health Agency of Sweden, the National Board of Health and Welfare, the Swedish National Veterinary Institute and Research Institutes of Sweden (RISE). In 2018, the programme committee is producing a joint strategic research agenda. This is intended to create synergies and to optimise the effect of existing research funding, and to avoid undesirable overlaps between research funding bodies.
Reference groups with researchers, patients and representatives from healthcare, farming, industry and other public authorities are also linked to the programme.